Assessment of Safety, Tolerability and Drug Levels of Exenatide Implant
← catalyst calendarSponsored by Vivani Medical, Inc (industry) · VANI — their whole pipeline →. With Avance Clinical Pty Ltd..
Phase
Phase 1
Status
Completed
Study type
Interventional
Design
Randomized · None · Treatment
Enrollment
24actual
Sites
1
Country
Australia
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2024-12-20 | actual | When the study began enrolling |
| Primary completion | 2025-08-21 | actual | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2025-08-21 | actual | The whole study's end, after follow-up |
| First posted | 2023-01-04 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2025-09-23 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Overweight and Obesity
- Type2diabetes
Interventions
- Combination product: Exenatide Implant — also filed as NPM115/NPM119
- Drug: Bydureon BCise (exenatide extended release)
- Drug: Semaglutide, 1.0 mg/mL — also filed as Wegovy, Ozempic
Primary outcomes
what the primary-completion date above is the date OFArea under the plasma concentration-time curve (AUC)
measured 9 weeks
Maximum plasma concentration observed (Cmax)
measured 9 weeks
Time to maximum plasma concentration observed (Tmax)
measured 9 weeks
Adverse events
measured 9 weeks
Permalink · VANI's whole pipeline · Catalyst calendar · Every registered study · What changed